Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Pettus

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Diabetes Technology & Therapeutics|March 5, 2024
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with SotagliflozinSchafer Boeder, Michael J Davies, Janet B McGill, et al.
Diabetes Care|February 26, 2026
Persistent Burden of Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Among People With Type 1 Diabetes Despite Technology Use: A Follow-up SurveyJennifer L Sherr, Rebecca L Molinsky, Tathabbai Pakalapati, et al.
Diabetes Technology & Therapeutics|September 18, 2018
Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled TrialRobert R Henry, Poul Strange, Rong Zhou, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2020
Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United StatesVijay N Joish, Fang Liz Zhou, Ronald Preblick, et al.
Diabetes Care|April 20, 2021
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100Ildiko Lingvay, John B Buse, Edward Franek, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 16, 2019
Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING StudyJeremy Pettus, Ronan Roussel, Fang Liz Zhou, et al.
Plos One|November 14, 2013
Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: implications for future use in cross-sectional assessmentGhanashyam Sarikonda, Jeremy Pettus, Sowbarnika Sachithanantham, et al.
Diabetes Technology & Therapeutics|July 24, 2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 DiabetesThomas Danne, Jeremy Pettus, Andrea Giaccari, et al.
Diabetes, Obesity & Metabolism|November 18, 2018
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetesKenneth Cusi, Fernando Bril, Diana Barb, et al.
Journal of Autoimmunity|January 7, 2014
CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetesGhanashyam Sarikonda, Jeremy Pettus, Sonal Phatak, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Diabetes Technology & Therapeutics|March 5, 2024
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with SotagliflozinSchafer Boeder, Michael J Davies, Janet B McGill, et al.
Diabetes Care|February 26, 2026
Persistent Burden of Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Among People With Type 1 Diabetes Despite Technology Use: A Follow-up SurveyJennifer L Sherr, Rebecca L Molinsky, Tathabbai Pakalapati, et al.
Diabetes Technology & Therapeutics|September 18, 2018
Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled TrialRobert R Henry, Poul Strange, Rong Zhou, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2020
Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United StatesVijay N Joish, Fang Liz Zhou, Ronald Preblick, et al.
Diabetes Care|April 20, 2021
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100Ildiko Lingvay, John B Buse, Edward Franek, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 16, 2019
Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING StudyJeremy Pettus, Ronan Roussel, Fang Liz Zhou, et al.
Plos One|November 14, 2013
Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: implications for future use in cross-sectional assessmentGhanashyam Sarikonda, Jeremy Pettus, Sowbarnika Sachithanantham, et al.
Diabetes Technology & Therapeutics|July 24, 2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 DiabetesThomas Danne, Jeremy Pettus, Andrea Giaccari, et al.
Diabetes, Obesity & Metabolism|November 18, 2018
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetesKenneth Cusi, Fernando Bril, Diana Barb, et al.
Journal of Autoimmunity|January 7, 2014
CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetesGhanashyam Sarikonda, Jeremy Pettus, Sonal Phatak, et al.
Pageof 5